...Emily Montal; Dianne Lumaquin; Yilun Ma; Shruthy Suresh; Richard M. White ABSTRACT Obesity is a rising concern and associated with an increase in numerous cancers, often in a sex-specific manner. Preclinical models are needed to deconvolute the intersection between obesity, sex and melanoma. Here...

...Jana Travnickova; Sarah Muise; Sonia Wojciechowska; Alessandro Brombin; Zhiqiang Zeng; Adelaide I. J. Young; Cameron Wyatt; E. Elizabeth Patton ABSTRACT Melanoma heterogeneity and plasticity underlie therapy resistance. Some tumour cells possess innate resistance, while others reprogramme during...

... studies have revealed recurrent fusions involving multiple kinases in a large proportion of Spitz tumors. In this study, we generated a transgenic zebrafish model of Spitz melanoma using a previously identified ZCCHC8-ROS1 fusion gene. Animals developed grossly apparent melanocytic proliferations as early...

...-based drug pellets that are consumed voluntarily. We applied this to zebrafish with BRAF-mutant melanoma, a model that has significantly advanced our understanding of melanoma progression, but not of drug resistance due to the limitations of current treatment methods. Zebrafish with melanomas responded...

... this difficulty, research has focused on the molecular dissection of the RAS pathway to gain a more-precise mechanistic understanding of its regulation, with the hope to identify new pharmacological approaches. Here, we review the current knowledge on the (dys)regulation of the RAS pathway, using melanoma...

... created a highly aggressive melanoma model via Cas9-mediated inactivation of Rb1 in the context of BRAF V600E in spatially constrained melanocytes. Unlike prior models that take ∼4 months to develop, we found that TEAZ leads to tumor onset in ∼7 weeks, and these tumors develop in fully immunocompetent...

... and isoflurane to an oral gavage technique for a non-toxic, non-invasive and long-term drug administration platform. As a proof of principle, we established drug efficacy of the FDA-approved BRAF V600E inhibitor, Vemurafenib, in adult zebrafish harboring BRAF V600E melanoma tumors. In the model, adult casper...